Free Trial

Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals logo
$5.36 +0.43 (+8.72%)
Closing price 04:00 PM Eastern
Extended Trading
$5.36 +0.00 (+0.09%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXRX vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTH

Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Recursion Pharmaceuticals vs. Its Competitors

Blueprint Medicines (NASDAQ:BPMC) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Blueprint Medicines has a net margin of -27.70% compared to Recursion Pharmaceuticals' net margin of -961.32%. Blueprint Medicines' return on equity of -64.60% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Blueprint Medicines-27.70% -64.60% -17.22%
Recursion Pharmaceuticals -961.32%-74.70%-54.02%

Blueprint Medicines presently has a consensus price target of $128.25, indicating a potential downside of 0.12%. Recursion Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 30.60%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Blueprint Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Blueprint Medicines
0 Sell rating(s)
17 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.24
Recursion Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Blueprint Medicines has higher revenue and earnings than Recursion Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$508.82M16.30-$67.09M-$2.47-51.98
Recursion Pharmaceuticals$58.84M37.03-$463.66M-$1.77-3.03

In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Blueprint Medicines. MarketBeat recorded 18 mentions for Recursion Pharmaceuticals and 6 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.68 beat Recursion Pharmaceuticals' score of 0.49 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Blueprint Medicines
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Recursion Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Blueprint Medicines has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Summary

Recursion Pharmaceuticals beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.18B$2.37B$5.46B$8.92B
Dividend YieldN/A1.78%5.24%4.04%
P/E Ratio-3.038.9127.0120.12
Price / Sales37.03499.49380.1493.34
Price / CashN/A21.7726.2128.59
Price / Book2.054.537.995.57
Net Income-$463.66M$31.26M$3.16B$248.40M
7 Day Performance4.48%5.57%3.69%6.04%
1 Month Performance-2.37%5.48%2.90%7.69%
1 Year Performance-27.57%1.14%34.30%20.97%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXRX
Recursion Pharmaceuticals
1.9175 of 5 stars
$5.36
+8.7%
$7.00
+30.6%
-32.7%$2.18B$58.84M-3.03400Trending News
Analyst Forecast
High Trading Volume
BPMC
Blueprint Medicines
1.516 of 5 stars
$128.14
+0.0%
$128.06
-0.1%
+15.0%$8.28B$562.12M-51.88640
BBIO
BridgeBio Pharma
4.6714 of 5 stars
$43.03
-4.1%
$58.85
+36.8%
+68.9%$8.17B$221.90M-12.19400
VRNA
Verona Pharma PLC American Depositary Share
2.6315 of 5 stars
$94.57
+0.8%
$101.10
+6.9%
+466.1%$8.05B$42.28M-47.2930Positive News
ROIV
Roivant Sciences
1.5227 of 5 stars
$11.26
-1.1%
$17.50
+55.4%
+0.8%$7.65B$29.05M-45.04860
ELAN
Elanco Animal Health
2.3542 of 5 stars
$14.25
-0.3%
$15.17
+6.4%
+1.8%$7.08B$4.44B19.269,000Analyst Upgrade
RVMD
Revolution Medicines
4.5679 of 5 stars
$36.88
-0.1%
$67.58
+83.3%
-2.3%$6.87B$11.58M-9.22250Positive News
LEGN
Legend Biotech
3.0626 of 5 stars
$35.80
+3.4%
$76.20
+112.8%
-22.5%$6.58B$627.24M-60.682,609Analyst Forecast
GRFS
Grifols
4.0961 of 5 stars
$8.93
+0.8%
$10.30
+15.3%
+26.0%$6.14B$7.81B7.6323,822News Coverage
Analyst Upgrade
TGTX
TG Therapeutics
3.9016 of 5 stars
$35.98
-2.0%
$40.80
+13.4%
+89.3%$5.71B$329M149.92290News Coverage
Positive News
LNTH
Lantheus
4.4243 of 5 stars
$82.20
+0.9%
$130.50
+58.8%
+0.4%$5.69B$1.53B23.35700

Related Companies and Tools


This page (NASDAQ:RXRX) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners